Introduction
============

*Staphylococcus aureus* is a major pathogen for animals and humans, which contributes to a variety of severe infections, including bacteremia, meningitis, endocarditis, skin and wood infection or other diseases for animals and humans ([@B5]; [@B31]; [@B6]). More importantly, *S. aureus* plays an important role in the food contamination by foodborne pathogens. Food poisoning caused by staphylococcal enterotoxin (SE) is a pressing worldwide health problem ([@B34]; [@B25]). In spite of the progress in antimicrobial therapy, treatment of *S. aureus* infection has become more and more challenging because drug-resistance of *S. aureus* has increased globally over the past decade. The methicillin-resistant *S. aureus* (MRSA) and vancomycin-resistant *S. aureus* (VRSA) were particularly reported and well documented ([@B24]; [@B32]).

In veterinary medicine, cefquinome (CEQ) has been licensed in European countries by virtue of its broad antibacterial spectrums and remarkable antibacterial activities. Despite of this, the cephalosporins should be in prudent use considering the escalating antimicrobial resistance. Evidence has showed that different animal species may harbor the same resistance determinant and are recognized as possible reservoirs of antimicrobial-resistant bacteria ([@B23]). It has been also observed that cefquinome exerted a selective effect on *bla*~CTX-M~ producing *Escherichia coli* strains ([@B10]). Therefore, further information concerning the ability of cefquinome to prevent occurring of resistant strains seems to be investigated.

Since mutant prevention concentration (MPC) of antibiotics was first described by [@B16], it has been successfully applied to evaluate the ability of antibiotics that restrict the selection of resistant strains ([@B2]; [@B1]; [@B36]; [@B7]) and optimize the current dosing regimens of antibiotics to slow the emergence of resistant strains. MPC was taken as the lowest doubling dilution drug concentration that prevented a population of 10^10^ colony forming unit (CFU)/mL or even more microorganisms from first-step mutation. Zone of the drug concentrations between minimum inhibitory concentration (MIC) and MPC was defined as the mutant selection window (MSW). MPC and MSW concepts, representing the ability of antibiotics to select resistant strains, have been tested in various *in vitro* studies ([@B2]; [@B14]; [@B18]), in *ex vivo* pharmacodynamic studies ([@B8]) and in *in vivo* studies ([@B13]; [@B15]). Here, we developed an *in vitro* kinetic model to investigate the relationship between pharmacokinetic/pharmacodynamic (PK/PD) indices of cefquinome with terminal half-lives (t~1/2β~) of 3 or 6 h and resistance development of *S. aureus* ATCC25923.

Materials and Methods {#s1}
=====================

Antimicrobial Agents, Medium, and Bacterial Strains
---------------------------------------------------

Raw material of cefquinome (purity of 84.1%) was obtained from Hebei yuanzheng Pharmaceutical Enterprise, Co., Ltd. Mueller-Hinton broth (MHB) and agar were purchased from Guangzhou huankai Comapany. *S. aureus* ATCC 25923 was purchased from the China Institute of Veterinary Drug Control (Beijing, China).

*In Vitro* Susceptibility Testing
---------------------------------

The MIC of CEQ against *S. aureus* with an inoculum of 5 × 10^5^ CFU/mL was determined by standard agar dilution method established by the Clinical and Laboratory Standards Institute (CLSI).

Measurement of MIC~99~, Mutant Prevention Concentration (MPC) and Selection Index (SI)
--------------------------------------------------------------------------------------

The MIC~99~ was defined as the drug concentration that inhibited 99% of bacteria colony formation. MPC was reckoned as the lowest cefquinome concentration blocking ≥10^10^ CFU/mL inoculants growth. The measurements of MIC~99~ and MPC were mainly based on the method reported by [@B39] with slight modification. For MIC~99~, agar plates containing a series of cefquinome (concentrations ranging from 0.5 to 0.164 μg/mL) at 20% per sequential decrease were prepared. 3 × 10^7^ CFU/mL *S. aureus* suspension in logarithmic phase of growth was then subjected to serial 10-fold dilutions with MHB to 3 × 10^2^ CFU/mL bacteria. Again, 100 μL of each dilution was plated onto the agar plates containing the series of CEQ concentrations mentioned above and incubated at 37°C overnight. Bacterial colonies that recovered growth in each dilution were counted. Drug concentrations versus the percentages of colony recovery were plotted and the interpolation method was adopted to calculate the cefquinome concentration blocking 99% bacteria growth.

The determination of MPC was similar to that of MIC~99~. Instead, 100 μL of 10^10^ CFU/mL inoculants was spread on agar plates containing a series of antimicrobial concentrations. The lowest antimicrobial concentration preventing bacterial colony formation at 72 h after incubation was measured as provisional mutant prevention concentration (MPC~pr~). A second determination that utilized linear MPC~pr~ decreases (about 20% per sequential decrease) was performed. MPC was the lowest CEQ concentration preventing 100% growth of *S. aureus* colony.

The calculated ratio of MPC/MIC~99~ for *S. aureus* was defined as selection index (SI) of cefquinome.

*In Vitro* Dynamic PK/PD Model Simulation
-----------------------------------------

A previous described dynamic model ([@B22]) with modification was developed in this study. One-compartment open model with first-order absorption of pharmacokinetics for cefquinome was simulated. The schematic representation of *in vitro* PK/PD model used is depicted in **Figure [1](#F1){ref-type="fig"}**. Briefly, the system was mainly composed of three sealed containers (compartments) and they were connected with peristaltic pumps in line, each containing sterile MHB and a magnetic stirrer to ensure adequate mixing. One 500 mL sealed compartment containing 300 mL MHB, provided with either a bacterial culture alone (control growth experiments) or a bacterial culture plus antibiotic (killing/re-growth experiments), acted as the central chamber. Another 100 mL sealed container charged with 60 mL of sterile MHB, acted as the absorption chamber, with desired calculated drug concentrations. The third one was used to provide fresh MHB. Waste was also collected. Peristaltic pumps circulated fresh broth to central and absorption compartments at the desired flow rate. The flow rate of the pump was set on the basis of the terminal half-life being simulated. A series of dosage regimens were designed to generate different CEQ concentration profiles with terminal half-lives of 3 and 6 h for three consecutive administrations in this apparatus.

![**Scheme of the *in vitro* dynamic model for bactericidal kinetics**.](fmicb-07-00466-g001){#F1}

*In Vitro* PK/PD Model and CEQ Dosing Regimens
----------------------------------------------

The apparatus ran under 37°C. The elimination terminal half-lives of cefquinome reported in the literature varied from 0.5 to 10 h ([@B29]; [@B27]; [@B3]; [@B35]; [@B37]; [@B41]; [@B17]), therefore, 3 and 6 h were selected in our study. Peristaltic pumps circulated fresh MHB medium to and from the central compartment at a flow rate of 15.75 r/min for t~1/2β~ of 3 h or 7.86 r/min for t~1/2β~ of 6 h, respectively. 3 mL bacterial suspensions (10^8^ CFU/mL) at the logarithmic phase were injected into the central compartment container. The bacteria were incubated in the model for 2 h to result in exponentially growing cultures before addition of cefquinome. Antibiotic doses were calculated to generate CEQ initial concentrations of 1/2MIC, MIC, 2MIC, 4MIC, 8MIC, and 16MIC levels, respectively. The *in vitro* pharmacokinetics of cefquinome for all doses after three consecutive administrations with 24 h interval for terminal half-lives of 3 and 6 h were simulated.

Quantification of Cefquinome in MHB
-----------------------------------

Samples were collected from the central compartment immediately before and at 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, and 24.0 h after the first and second administration, and 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 24.0, 30.0, 36.0, and 48.0 h after the third administration. These samples were stored at -20°C until analysis.

1.5 mL of MHB was extracted for the determination of cefquinome. The concentrations of cefquinome in MHB were analyzed by high-performance liquid chromatography-MS/MS (HPLC-MS/MS) with an assay range of 0.005--0.5 μg/mL. The protein in MHB sample (1 mL) was precipitated by 2 mL acetonitrile, and the supernatant was directly injected into HPLC-MS/MS after high speed centrifugation. Analysis of quality control (QC) samples at three levels (0.01, 0.05, 0.2 μg/mL) showed that the recoveries of the method were above 70%; the intra-day and inter-day coefficients of variation were within 15%. The pharmacokinetic parameters were calculated by a WinNonlin software (version 5.2.1; Pharsight Corporation, USA).

*In Vitro* Time-Kill Experiments and Susceptibility Testing of *S. aureus*
--------------------------------------------------------------------------

To measure the antimicrobial effect of cefquinome with different terminal half-lives against *S. aureus*, the colony count and susceptibility of bacteria in each time point were performed after treatment. Half of each sample was subjected to time-kill kinetic assays. Samples (100 μL) in series of 10-fold dilution with sterile saline (0.9% NaCl) were spread onto Mueller-Hinton agar to determine the number of total or resistant cells. The log~10~ of surviving *S. aureus* cells (CFU/mL) was plotted against each time point. The other half of each sample was used for the susceptibility test. MIC values of bacteria post-exposed in each time point was conducted using tube dilution method according to the criteria established by the [@B11].

Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Analysis
------------------------------------------------------------

By using the individual pharmacokinetic result from each *in vitro* dosage regimen, the following PK/PD parameters were obtained: ratio of area under the curve of cefquinome concentration versus time to MIC (AUC~0-∞~/MIC) or (AUC~0-24~ ~h~/MIC), ratio of area under the curve of cefquinome concentration exceeding MIC to MIC (AUC~C~ ~\>~ ~MIC~/MIC), time of concentration above MIC (T \> MIC) or MPC (T \> MPC), time of concentration within MPC and MIC (T~MSW~) or expressed as percentage (T~MSW~%), ratio of MIC~72~ to MIC~initial~ (MIC~72~/MIC~initial~).

Gaussian function was used to simulate the correlation of MIC~72~ ~h~/MIC~initial~ with T~MSW~% (percentage of the time during which cefquinome concentrations were inside the MSW). The formula was as follows:
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where A was the area under curve and upper baseline; x~0~ was the minimum value of T~MSW~% which resulted in the maximum MIC~72~ ~h~/MIC~initial~.

Results
=======

MIC~99~ and MPC
---------------

The MIC~99~ and MPC of cefquinome against *S. aureus* ATCC 25923 were 0.4 and 4.096 μg/mL, respectively. So the SI was 10.24 (MPC/MIC~99~).

*In Vitro* Simulated Pharmacokinetics
-------------------------------------

The *in vitro* simulated time-concentration curves for cefquinome with terminal half-lives of 3 and 6 h are shown in **Figure [2](#F2){ref-type="fig"}**. This study used time-concentration curves of the unbound fractions of cefquinome in Mueller-Hinton broth. The maximum concentrations were approximately equal to 1/2MIC to 16-fold MIC of cefquinome against *S. aureus* ATCC 25923 after three consecutive administrations. The MPC and MIC levels were also indicated in the simulated time-concentration curves.

![**Concentration-time curves of cefquinome in the *in vitro* pharmacokinetics model of two terminal half-lives (t~1/2β~).** The horizontal lines indicate the MPC (4.096 μg/mL) and MIC (0.4 μg/mL) for *Staphylococcus aureus* ATCC 25923, respectively. **(A)** t~1/2β~ = 3 h, **(B)** t~1/2β~ = 6 h.](fmicb-07-00466-g002){#F2}

The Bacteria Killing Curves in *In Vitro* Models
------------------------------------------------

Time-killing curves of *S. aureus* ATCC 25923 in the *in vitro* model under different dosing regimens are shown in the following **Figure [3](#F3){ref-type="fig"}**. For a t~1/2β~ of 3 h multiple dosages, bacteriostatic or bactericidal action was observed when maximum cefquinome concentrations were equal to MIC or over MIC levels (dosages ranged from 0.672 to 10.767 mg). For a t~1/2β~ of 6 h multiple dosages, continuous bactericidal action was observed when maximum cefquinome concentrations were at 4MIC, 8MIC, 16MIC (dose ranged from 2.691 to 10.767 mg), and the continuous time of bactericidal action at 16MIC was the longest among three concentrations.

![**Viable counts of *S. aureus* ATCCC 25923 in time-kill assays with cefquinome in different terminal half-lives (t~1/2β~) at cefquinome concentrations from a half to 16-fold the minimum inhibitory concentration (MIC), in comparison with a cefquinome-free control. (A)** t~1/2β~ = 3 h, **(B)** t~1/2β~ = 6 h.](fmicb-07-00466-g003){#F3}

Loss of Susceptibility to Cefquinome
------------------------------------

Compared to drug-free group, loss of susceptibility was observed in MIC, 2MIC, and 4MIC concentration groups after administrations, as shown in **Figure [4](#F4){ref-type="fig"}**. For multiple dosages with t~1/2β~ of 3 h, the bacterial MICs after administration increased to 4.0, 8.0, and 1.0 μg/mL for MIC, 2MIC, and 4MIC groups, respectively. For multiple dosages with t~1/2β~ of 6 h, the bacterial MICs after administration increased to 2.0, 4.0, and 0.8 μg/mL for MIC, and 2MIC, and 4MIC concentration administrations, respectively. The MIC values did not change through the whole experiment period in 8MIC and 16MIC administration groups with two different terminal half-lives.

![**Typical susceptibility responses of *S. aureus* ATCCC 25923 observed in the *in vitro* PK/PD model simulating the pharmacokinetics of cefquinome with different terminal half-lives (t~1/2β~).(A)** t~1/2β~ = 3 h, **(B)** t~1/2β~ = 6 h.](fmicb-07-00466-g004){#F4}

Correlation of PK/PD Indices with Resistance Selection
------------------------------------------------------

Pharmacokinetic/pharmacodynamic indices, such as AUC~24~ ~h~/MIC (where AUC~24h~ is the area under the drug concentration time curve in a 24 h interval) and time above the MIC, provide an empirical way to relate antimicrobial dose to favor the treatment effect of bactericidal agents. Relationships between PK/PD indices and loss of susceptibility are shown in **Table [1](#T1){ref-type="table"}**. For cephalosporin, T \> MIC was the index most commonly associated with restricting susceptible cell growth. When T \> MIC attained 17.14 h or T \> MIC% attained 24%, the MIC value of cefquinome against *S. aureus* increased to 16-fold of initial value at 72 h after multiple administrations in groups with t~1/2β~ of 3 h. Similarly, in groups with t~1/2β~ of 6 h, when T \> MIC = 34.28 h or T \> MIC% = 48%, the value of cefquinome MIC increased to eightfold of initial value after multiple dosages.

###### 

Pharmacokinetic/pharmacodynamic (PK/PD) indices of antimicrobial efficacy and risk of resistance selection amongst *Staphylococcus aureus* ATCC 25923 over the complete dosing interval following PK simulations of three consecutive administrations of cefquinome in t~1/2β~ of 3 and 6 h.

  t~1/2β~ (h)   D (mg)   $\frac{AUC_{C > {MIC}}}{MIC}\left( h \right)$   $\frac{AUC_{24}}{MIC}{\,\left( h \right)}$   T \> MIC (h)   T \> MPC (h)   T~MSW~ (h)   T~MSW~%   T \> MIC%   $\frac{MIC_{72}}{MIC_{initial}}$
  ------------- -------- ----------------------------------------------- -------------------------------------------- -------------- -------------- ------------ --------- ----------- ----------------------------------
  3             1/2MIC   0                                               3.22                                         0              0              0            0         0           1
                MIC      6.41                                            6.43                                         8.11           0              8.11         11        11          8
                2MIC     25.89                                           12.89                                        17.14          0              17.14        24        24          16
                4MIC     64.68                                           25.76                                        26.13          0              26.13        36        36          2
                8MIC     142.34                                          51.52                                        35.13          7.81           27.32        38        49          1
                16MIC    297.75                                          103.07                                       44.14          16.82          27.32        38        61          1
                                                                                                                                                                                       
  6             1/2MIC   0                                               5.96                                         0              0              0            0         0           1
                MIC      12.81                                           11.92                                        16.21          0              16.21        23        23          4
                2MIC     51.77                                           23.89                                        34.28          0              34.28        48        48          8
                4MIC     129.35                                          47.73                                        52.26          0              52.26        73        73          1.5
                8MIC     284.68                                          95.45                                        70.26          15.63          54.64        76        98          1
                16MIC    595.50                                          190.96                                       88.28          33.64          54.64        76        123         1

Other PK/PD indices also showed correlation with the selection of resistance (**Table [1](#T1){ref-type="table"}**). When T~MSW~ and T~MSW~% were 17.14 h and 24%, the MIC increased to 16-fold of initial value in groups with t~1/2β~ of 3 h after multiple dosages, and the MIC increased to eightfold of initial value When T~MSW~ and T~MSW~% were 34.28 h and 48% with t~1/2β~ of 6 h after multiple dosages, respectively.

Correlation Analysis of MIC Increase with T~MSW~%
-------------------------------------------------

According to Gaussian function and regression analysis results, the bacteria was prone to develop resistance when T~MSW~% was about 20% (x~0~ = 0.2027) in groups with t~1/2β~ of 3 h after multiple dosages (*R*^2^= 0.9989), and T~MSW~% was about 40% (x~0~ = 0.4102) in groups with t~1/2β~ of 6 h after multiple dosages (*R*^2^ = 0.9986), respectively, as shown in **Figure [5](#F5){ref-type="fig"}**. Those results were consistent with the data from **Table [1](#T1){ref-type="table"}**.

![**Relationship between the T~MSW~% and MIC~72~/MIC~0~ for *S. aureus* ATCC 25293 exposed to cefquinome in the *in vitro* model with two terminal half-lives (t~1/2β~). (A)** t~1/2β~ = 3 h, **(B)** t~1/2β~ = 6 h.](fmicb-07-00466-g005){#F5}

Discussion
==========

Antimicrobial resistance has been a global problem and a great number of strategies have been proposed to slow the emergence of resistance ([@B33]; [@B26]). *In vivo* or *in vitro* PK/PD models have previously been applied to optimize the dosage regimen of various antibiotics in the literature ([@B14]; [@B19]; [@B4]; [@B21]). However, PK/PD model has been renewably used to investigate relationship of bacterial resistance with AUC/MIC, C~max~/MIC and T \> MIC, recently. In the present study, we simulated the cefquinome pharmacokinetic profiles with different terminal half-lives using this dynamic model and tried to predict the selection of resistant *S. aureus* with some indices, such as T \> MIC and T~MSW~%.

It is believed that integration of drug pharmacokinetics, mutant prevention concentration is helpful in slowing the emergence of resistance. In this experiment, the MPC and MSW of cefquinome against *S. aureus* ATCC25923 were determined. The SI, ratio of MPC to MIC~99~, is the ability of a drug to select resistant mutants ([@B38]). In other word, the bigger the SI is, the easier the drug is to induce resistance. The SI of cefquinome against *S. aureus* ATCC25923 was 10.24 in our study, which suggested that cefquinome could induce *S. aureus* resistant mutation easily and effectively.

T \> MIC was regarded as a promising predictor for the efficacy of cephalosporins. Previous pharmacodynamic studies have addressed separate issues around the relationships between T \> MIC and efficacy for cephalosporins. [@B12] has reviewed the data of efficacy for cephalosporins against *Enterbacteriaceae*, *streptococci* and *S. aureus* in several animal infection models and found that the time above MIC required for a bacteriostatic effect against strains of *Enterbacteriaceae*, *Streptococci* were generally 60--70%, and 40--50% for *S. aureus*, respectively. In our study, the value of T \> MIC for maximal killing was 40∼60% for cefquinome against *S. aureus* reference strain. In consistent with the widespread idea that antibacterial efficacy of β-lactams depend on T \> MIC, the effect of cefquinome against *S. aureus* in our study exhibited similar correlation. As observed in **Figure [3](#F3){ref-type="fig"}**, killing curves of *S. aureus* exposed to each dose of cefquinome showed the typical pattern of time-dependent bactericidal action. The similar observation was also reported for other β-lactam drugs in previous studies ([@B30]; [@B9]). Considering that the T \> MIC was one of the most important parameters for optimal dosage regimen, T \> MIC was selected as a parameter to evaluate resistant mutation in this article. In the present study, the values of T \> MIC ranging from 8.11 to 17.14 h were dangerous zones for inducing resistant mutation in groups with t~1/2β~ of 3 h after multiple dosages, and values ranging from 16.21 to 34.28 h were dangerous zones for inducing resistant mutation in groups with t~1/2β~ of 6 h multiple dosages. Compared these values with previously reported study data that T \> MIC value ranged from 42 to 54 h for cefquinome in dairy cows ([@B41]), the prevention of selecting resistant *S. aureus* strains seems to be achieved by the present dosage regimens approved by the European Medicines Agency (EMA) for the treatment of dairy cow mastitis.

T~MSW~ is another important parameter used for evaluating resistant mutation. A previous study conducted in a rabbit lung infection model with *Streptococcus pneumonia* showed that the selection of resistant bacteria occurred systematically when concentrations of gatifloxacin were within the MSW (T~MSW~) for more than 45% of the treatment duration ([@B14]). Another experiment in rabbits infected by *S. aureus* also showed that time in the MSW \> 33% was preferable to select mutants ([@B15]). When the abilities of the indices T~MSW~, AUC~24~ ~h~/MIC, C~max~/MIC to predict the selection of resistant bacteria were compared, only T~MSW~ appeared to be a good predictor of the prevention of resistance ([@B19]). In this study, T~MSW~ was also used to predict selection of resistant *S. aureus* against cefquinome. It was clearly determined that when T~MSW~ was above 36% in groups with t~1/2β~ of 3 h after multiple dosages or above 73% in groups with t~1/2β~ of 6 h after multiple dosages, cefquinome could restrict the resistant mutation.

In the present investigation, the bacterial resistant mutation was affected by different terminal half-lives and dosages. Within the group of the same terminal half-life (3 or 6 h), the bacterial resistant mutation happened under the condition of relative low dosage (maximum concentrations were 2MIC and 4MIC). When the maximum concentration was over 8MIC, resistant mutation was prevented. In the same dosages (maximum concentration was 2MIC or 4MIC), the MIC~72~ ~h~ increased from 8- to 16-fold in groups with t~1/2β~ of 3 h after multiple dosages and increased from 4- to 8-fold in groups with t~1/2β~ of 6 h after multiple dosages, respectively. Those results suggested that the bacterial resistant mutation might happen at a low concentration. In high dosages or long terminal half-lives, the drug concentrations might exceed the MPC value, the upper boundary of MSW, and the resistant mutation could be inhibited. The conclusion from this study was consistent with other similar studies ([@B15]; [@B19]; [@B40]).

The limitation of the study was that only one reference strain was used to simulate the efficacy of cefquinome in this *in vitro* model; however, the multi-resistance is becoming an urgent trend all over the world. It may be reasonable that more clinical isolates of *S. aureus* could be used for further study. [@B20] used two methicillin-resistant strains of *S. aureus*, ATCC 6538 and ATCC 43300, to study the enrichment of ciprofloxacin resistant mutation in an *in vitro* dynamic model. [@B28], chose three clinical isolates of *S. aureus*, SA99, RN450 and RN450-A1, to analyze the enrichment of levofloxacin resistant mutation with *in vitro* dynamic model. From the results obtained in the dynamic model, more clinical isolates could be used to study resistant mutation easily based on the substantial method. Moreover, to our knowledge, evaluation of antimicrobial activity for cefquinome with different terminal half-lives is scarce. Considering the fact that cefquinome is the time-dependent drug, it is positive to study the correlation resistant mutation with different terminal half-life conditions. Another limitation of the current study was the absence of resistance mechanisms of *S. aureus* observed *in vitro*. Therefore, the pattern of *S. aureus* resistant to cefquinome, such as production of β-lactamases, alteration of drug targets, porin-mediated resistance, and/or eﬄux-mediated resistance, needs confirmation in the further study.

Conclusion
==========

The present study of resistant mutation with *S aureus* ATCC 25923 exposed to cefquinome with two different terminal half-lives in *in vitro* dynamic models supports the MSW hypothesis and provides some useful parameters to predict the resistant mutation, especially T \> MIC and T~MSW~%. Further study will concentrate on more clinical isolates which could be used for verification of these results and resistance patterns of *S. aureus* resistant to cefquinome.

Author Contributions
====================

All authors listed, have made substantial, direct and intellectual contribution to the work, and approved it for publication.

Conflict of Interest Statement
==============================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors would like to thank the financial support by the Natural Science Foundation of China (grant number 31172366) and 973 program (grant number 2013CB127200/2013CB127203).

[^1]: Edited by: *Alexandre Gonçalves, Universidade de Trás-os-Montes e Alto Douro, Portugal*

[^2]: Reviewed by: *Dmitri Debabov, NovaBay Pharmaceuticals, Inc., USA; William Farias Porto, Universidade Católica de Brasília, Brazil*

[^3]: ^†^*These authors have contributed equally to this work.*

[^4]: This article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology
